Search Within

Advanced Practice Providers

  1. "Gastrointestinal Oncology Service"
Formats
  1. Meeting Abstract (72)
  2. Journal Article (59)
  3. Research Letter (2)
  4. Book Section (1)
  5. Editorial (1)
  6. Miscellaneous (1)
  7. Review (1)
Groups
  1. Department of Medicine (137)
  2. Gastrointestinal Oncology Service (137)
  3. Solid Tumor Oncology Division (137)
  4. Nursing (115)
  5. Center for Pancreatic Cancer Research (62)
  6. Survivorship Research (55)

More Groups

People
  1. Ellen Hollywood (37)
  2. Leonard Saltz (31)
  3. Armin Shahrokni (30)
  4. Diane Reidy (28)
  5. Andrew Epstein (27)
  6. Beatriz Korc-Grodzicki (26)

More People

Years
  1. 2025 (4)
  2. 2024 (4)
  3. 2023 (6)
  4. 2022 (9)
  5. 2021 (14)
  6. 2020 (13)

More Years

Publications
  1. Journal of Clinical Oncology (56)
  2. Journal of Pain and Symptom Management (8)
  3. JCO Oncology Practice (7)
  4. Journal of the American Geriatrics Society (5)
  5. Annals of Oncology (4)
  6. Cancer (4)

More Publications

Publishers
  1. American Society of Clinical Oncology (69)
  2. Elsevier Inc. (15)
  3. Wiley Blackwell (11)
  4. Oxford University Press (7)
  5. American Association for Cancer Research (5)
  6. Springer (4)

More Publishers

Results (137)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Correlation of clinical and immunological data in a metastatic melanoma patient with heterogeneous tumor responses to ipilimumab therapy
    Journal Article

    Yuan, J.; Page, D. B.; Ku, G. Y.; Li, Y.; Mu, Z.; Ariyan, C.; Gallardo, H. F.; Roman, R. A.; Heine, A. I.; Terzulli, S. L.; more...
    Cancer Immunity (2010)

    Fulltext@MSK | Save
  • Phase II study of bevacizumab in combination with cetuximab plus irinotecan in irinotecan-refractory colorectal cancer (CRC) patients who have progressed on a bevacizumab-containing regimen (The BOND 2.5 Study)
    Meeting Abstract

    Segal, N. H.; Reidy-Lagunes, D.; Capanu, M.; Kemeny, N.; Chung, K.; Kelsen, D.; Hollywood, E.; Goodman-Davis, N.; Saltz, L. B.
    Journal of Clinical Oncology (2009)

    Fulltext@MSK | Save
  • CTLA-4 blockade enhances polyfunctional NY-ESO-1 specific T cell responses in metastatic melanoma patients with clinical benefit
    Journal Article

    Yuan, J.; Gnjatic, S.; Li, H.; Powel, S.; Gallardo, H. F.; Ritter, E.; Ku, G. Y.; Jungbluth, A. A.; Segal, N. H.; Rasalan, T. S.; more...
    Proceedings of the National Academy of Sciences of the United States of America (2008)

    Fulltext@MSK | Save
  • A phase 1 dose-escalation study of irinotecan in combination with 17-allylamino-17-demethoxygeldanamycin in patients with solid tumors
    Journal Article

    Tse, A. N.; Klimstra, D. S.; Gonen, M.; Shah, M.; Sheikh, T.; Sikorski, R.; Carvajal, R.; Mui, J.; Tipian, C.; O'reilly, E.; more...
    Clinical Cancer Research (2008)

    Fulltext@MSK | Save
  • The pharmacokinetics, toxicities, and biologic effects of FK866, a nicotinamide adenine dinucleotide biosynthesis inhibitor
    Journal Article

    Holen, K.; Saltz, L. B.; Hollywood, E.; Burk, K.; Hanauske, A. R.
    Investigational New Drugs (2008)

    Fulltext@MSK | Save
  • Pharmacogenomic analysis of a randomized phase II trial (BOND 2) of cetuximab/bevacizumab/irinotecan (CBI) versus cetuximab/bevacizumab (CB) in irinotecan-refractory colorectal cancer
    Meeting Abstract

    Zhang, W.; Yang, D.; Capanu, M.; Hollywood, E.; Lue-Yat, M.; Borucka, E.; Azuma, M.; Gordon, M.; Saltz, L.; Lenz, H.
    Journal of Clinical Oncology (2007)

    Fulltext@MSK | Save
  • Bevacizumab 5mg/kg can be safely infused over 10 minutes
    Meeting Abstract

    Reidy, D. L.; Chung, K. Y.; Timoney, J. P.; Park, V.; Hollywood, E.; Sklarin, N.; Muller, R.; Saltz, L.
    Journal of Clinical Oncology (2007)

    Fulltext@MSK | Save
  • Molecular markers associated with response and clinical outcome to cetuximab/bevacizumab/irinotecan (CBI) versus cetuximab/bevacizumab (CB) in irinotecan-refractory colorectal cancer (BOND2)
    Meeting Abstract

    Azuma, M.; Yang, D.; Carpanu, M.; Hollywood, E.; Lue-Yat, M.; Zhang, W.; Danenberg, K. D.; Danenberg, P. V.; Saltz, L.; Lenz, H.
    Journal of Clinical Oncology (2007)

    Fulltext@MSK | Save
  • Randomized phase II trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer: The BOND-2 study
    Journal Article

    Saltz, L. B.; Lenz, H. J.; Kindler, H. L.; Hochster, H. S.; Wadler, S.; Hoff, P. M.; Kemeny, N. E.; Hollywood, E. M.; Gonen, M.; Quinones, M.; more...
    Journal of Clinical Oncology (2007)

    Fulltext@MSK | Save
  • Bevacizumab 5 mg/kg can be infused safely over 10 minutes
    Journal Article

    Reidy, D. L.; Chung, K. Y.; Timoney, J. P.; Park, V. J.; Hollywood, E.; Sklarin, N. T.; Muller, R. J.; Saltz, L. B.
    Journal of Clinical Oncology (2007)

    Fulltext@MSK | Save